▁requiring ▁prompt ▁inter vention . ▁Where as ▁the ▁least ▁severe ▁form ▁( type ▁ 4 / ad ult ▁on set ), ▁individuals ▁may ▁not ▁seek ▁the ▁certain ▁aspects ▁of ▁care ▁until ▁later ▁( dec ades ) ▁in ▁life . ▁While ▁types ▁of ▁S MA ▁and ▁individuals ▁among ▁each ▁type ▁may ▁differ , ▁therefore ▁specific ▁aspects ▁of ▁an ▁individual ' s ▁care ▁can ▁differ . ▁ ▁Medic ation ▁N us in ers en ▁is ▁used ▁to ▁treat ▁sp inal ▁mus cular ▁at ro phy . ▁It ▁is ▁an ▁ant is ense ▁nucle ot ide ▁that ▁mod ifies ▁the ▁alternative ▁sp lic ing ▁of ▁the ▁SM N 2 ▁gene . ▁It ▁is ▁given ▁directly ▁to ▁the ▁central ▁nerv ous ▁system ▁using ▁an ▁intr at he cal ▁injection . ▁N us in ers en ▁prolong s ▁surv ival ▁and ▁impro ves ▁motor ▁function ▁in ▁inf ants ▁with ▁S MA . ▁It ▁was ▁approved ▁in ▁the ▁US ▁in ▁ 2 0 1 6 ▁and ▁in ▁the ▁EU ▁in ▁ 2 0 1 7 . ▁ ▁On as em n ogene ▁ab e par v ove c ▁is ▁a ▁gene ▁ther apy ▁treatment ▁which ▁uses ▁self - com plement ary ▁ad eno - associ ated ▁virus ▁type ▁ 9 ▁( sc AA V - 9 ) ▁as ▁a ▁vector ▁to ▁deliver ▁the ▁SM N 1 ▁trans g ene . ▁As ▁an ▁int ra ven ous ▁form ulation , ▁it ▁was ▁approved ▁in ▁ 2 0 1 9 ▁in ▁the ▁US ▁to ▁treat ▁those ▁below ▁ 2 4 ▁months